The stock of Xencor Inc (NASDAQ:XNCR) is a huge mover today! About 135,265 shares traded hands. Xencor Inc (NASDAQ:XNCR) has risen 37.85% since April 4, 2016 and is uptrending. It has outperformed by 36.76% the S&P500.
The move comes after 6 months positive chart setup for the $792.28M company. It was reported on Nov, 4 by Barchart.com. We have $30.38 PT which if reached, will make NASDAQ:XNCR worth $427.83M more.
Xencor Inc (NASDAQ:XNCR) Ratings Coverage
Out of 5 analysts covering Xencor (NASDAQ:XNCR), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Xencor has been the topic of 7 analyst reports since August 5, 2015 according to StockzIntelligence Inc. MLV maintained it with “Buy” rating and $29 target price in Wednesday, August 5 report. The stock has “Outperform” rating given by Leerink Swann on Thursday, September 17. The stock has “Hold” rating given by Zacks on Saturday, August 8. The rating was initiated by Canaccord Genuity with “Buy” on Tuesday, December 22. The rating was upgraded by Zacks on Friday, September 4 to “Hold”. The firm has “Overweight” rating given on Tuesday, October 4 by Piper Jaffray. On Tuesday, March 8 the stock rating was maintained by Leerink Swann with “Outperform”.
According to Zacks Investment Research, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.”
Insitutional Activity: The institutional sentiment increased to 1.64 in 2016 Q2. Its up 0.40, from 1.24 in 2016Q1. The ratio increased, as 10 funds sold all Xencor Inc shares owned while 23 reduced positions. 13 funds bought stakes while 41 increased positions. They now own 27.63 million shares or 4.30% less from 28.87 million shares in 2016Q1.
Blackrock Institutional Trust Na, a California-based fund reported 622,507 shares. Qvt Limited Partnership last reported 386,925 shares in the company. Goldman Sachs Grp last reported 23,075 shares in the company. Rhenman Partners Asset Management Ab holds 0.76% of its portfolio in Xencor Inc (NASDAQ:XNCR) for 225,000 shares. Credit Suisse Ag holds 27,385 shares or 0% of its portfolio. Invesco Limited owns 121,421 shares or 0% of their US portfolio. Jpmorgan Chase And Company accumulated 0% or 288,950 shares. Geode Capital Llc has 236,224 shares for 0% of their US portfolio. Tiaa Cref Inv Limited Liability Corp owns 137,810 shares or 0% of their US portfolio. Moreover, Alliancebernstein Lp has 0% invested in Xencor Inc (NASDAQ:XNCR) for 82,990 shares. Victory Capital Mngmt has 0% invested in the company for 1,447 shares. Blackrock Inc reported 11,350 shares or 0% of all its holdings. Price T Rowe Assoc Inc Md, a Maryland-based fund reported 575,316 shares. The Delaware-based Blackrock Advsr Limited Co has invested 0% in Xencor Inc (NASDAQ:XNCR). Gsa Capital Prtnrs Ltd Liability Partnership has invested 0.03% of its portfolio in Xencor Inc (NASDAQ:XNCR).
Insider Transactions: Since May 24, 2016, the stock had 0 buys, and 18 selling transactions for $8.24 million net activity. 10,000 shares were sold by STAFFORD JOHN S III, worth $230,550. Another trade for 3,400 shares valued at $77,074 was made by CARTER BRUCE L A on Thursday, August 11. The insider Dahiyat Bassil I sold $872,028. Shares for $354,065 were sold by Desjarlais John R on Tuesday, August 23. $22,663 worth of Xencor Inc (NASDAQ:XNCR) was sold by Baracchini Edgardo Jr. $100,050 worth of Xencor Inc (NASDAQ:XNCR) was sold by Foster Paul A on Wednesday, August 3.
More important recent Xencor Inc (NASDAQ:XNCR) news were published by: Fool.com which released: “Why Xencor Inc’s Shares Are Skyrocketing Today” on June 28, 2016, also Fool.com published article titled: “This Caused Xencor Inc.’s Stock to Jump 11.6% in August”, Prnewswire.com published: “Xencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195” on September 15, 2016. More interesting news about Xencor Inc (NASDAQ:XNCR) was released by: Prnewswire.com and their article: “Xencor Doses First Patient in Lead Immuno-Oncology Bispecific Program …” with publication date: September 12, 2016.
XNCR Company Profile
Xencor, Inc., incorporated on June 8, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. The Company’s segment is related to the development of pharmaceutical products. The Firm uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. The Company’s clinical stage product candidates include XmAb5871, which is being developed for autoimmune disease, and XmAb7195, which is being developed for asthma and allergic diseases. The Company’s oncology product candidates are in preclinical stage, which include XmAb14045 for the treatment of acute myeloid leukemia (AML) and XmAb13676 for B-cell malignancy. In addition to its compounds in clinical development, the Company uses its XmAb technology to create antibody compounds which are licensed to other pharmaceutical and biotechnology companies for further development, which include XmAb5574/MOR208 (MOR208), an antibody drug candidate, and XmAb13551, a bispecific CD38 x CD3 preclinical candidate.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.